{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:43:21Z","timestamp":1793598201836,"version":"4.5.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Pioglitazone is considered a potential therapy for non-alcoholic fatty liver disease (NAFLD). However, different effects of pioglitazone on NAFLD have been demonstrated in diabetic and non-diabetic patients. Herein, a meta-analysis of randomized, placebo-controlled trials was carried out to indirectly compare pioglitazone in NAFLD patients with\n                      <jats:italic>vs<\/jats:italic>\n                      . without type 2 diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Randomized controlled trials (RCTs) of pioglitazone\n                      <jats:italic>vs<\/jats:italic>\n                      . placebo involving NAFLD patients with or without type 2 diabetes\/prediabetes collected from databases were enrolled into this analysis. Methodological quality was employed to evaluate the domains recommended by the Cochrane Collaboration. The analysis covered the changes in histology (fibrosis, hepatocellular ballooning, inflammation, steatosis), liver enzymes, blood lipids, fasting blood glucose (FBS), homeostasis model assessment-IR (HOMA-IR), weight and body mass index (BMI) before and after treatment, and adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The review covered seven articles, with 614 patients in total, of which three were non-diabetic RCTs. No difference was found in patients with\n                      <jats:italic>vs<\/jats:italic>\n                      . without type 2 diabetes in histology, liver enzymes, blood lipids, HOMA-IR, weight, BMI, and FBS. Moreover, no significant difference was revealed in adverse effects between NAFLD patients with diabetes and without DM, except the incidence of edema that was found to be higher in the pioglitazone group than in the placebo group in NAFLD patients with diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pioglitazone could exert a certain effect on alleviating NAFLD, which was consistent between non-diabetic NAFLD patients and diabetic NAFLD patients in improving histopathology, liver enzymes, and HOMA-IR and reducing blood lipids. Furthermore, there were no adverse effects, except the incidence of edema which is higher in the pioglitazone group in NAFLD patients with diabetes. However, large sample sizes and well-designed RCTs are required to further confirm these conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2023.1111430","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T09:09:09Z","timestamp":1680080949000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"14","author":[{"given":"Zeyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihua","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiageng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meidong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: The growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14709","article-title":"Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management","volume":"50","author":"Huang","year":"2020","journal-title":"Intern Med J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: A review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the united states: An analysis of national health and nutrition examination survey data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13637","article-title":"Management of patients with non-alcoholic steatohepatitis (NASH) in real life","volume":"38","author":"Serfaty","year":"2018","journal-title":"Liver Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2011.10.016","article-title":"Roles of PPARs in NAFLD: potential therapeutic targets","volume":"1821","author":"Tailleux","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B9","doi-asserted-by":"publisher","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Della Pepa","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14936","article-title":"Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence","volume":"10","author":"Bril","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04467.x","article-title":"Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis","volume":"32","author":"Rakoski","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: A meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","unstructured":"Cochrane handbook for systematic reviews of interventions2011"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90054-Q","article-title":"Variance imputation for overviews of clinical trials with continuous response","volume":"45","author":"Follmann","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.6099","article-title":"Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study","volume":"12","author":"Hajiaghamohammadi","year":"2012","journal-title":"Hepat Mon"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2012.10.010","article-title":"A randomized controlled trial comparing efficacy of pentoxifylline and pioglitazone on metabolic factors and liver histology in patients with non-alcoholic steatohepatitis","volume":"2","author":"Sharma","year":"2012","journal-title":"J Clin Exp Hepatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00457-4","article-title":"A pilot study of vitamin e versus vitamin e and pioglitazone for the treatment of nonalcoholic steatohepatitis","volume":"2","author":"Sanyal","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000981","article-title":"Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease","volume":"29","author":"Yaghoubi","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13293-020-00344-1","article-title":"Gender differences in the efficacy of pioglitazone treatment in nonalcoholic fatty liver disease patients with abnormal glucose metabolism","volume":"12","author":"Yan","year":"2021","journal-title":"Biol Sex Differ"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04405.x","article-title":"Pioglitazone in the treatment of NASH: the role of adiponectin","volume":"32","author":"Gastaldelli","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15131","article-title":"Use of metabolic syndrome severity to assess treatment with vitamin e and pioglitazone for non-alcoholic steatohepatitis","volume":"36","author":"Gurka","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25805","article-title":"Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin e versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study","volume":"56","author":"Bell","year":"2012","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cct.2008.09.003","article-title":"Pioglitazone versus vitamin e versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design","volume":"30","author":"Chalasani","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30418","article-title":"Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: Results from the nonalcoholic steatohepatitis clinical research network treatment trials","volume":"70","author":"Brunt","year":"2019","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15005","article-title":"PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.013","article-title":"Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis","volume":"47","author":"Balas","year":"2007","journal-title":"J Hepatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12833","article-title":"Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial","volume":"11","author":"Portillo-Sanchez","year":"2019","journal-title":"J Diabetes"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13035","article-title":"NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels","volume":"41","author":"Corey","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin e for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001369","article-title":"Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial","volume":"31","author":"Anushiravani","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin e, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19046","article-title":"Pioglitazone for the treatment of metabolic-associated fatty liver disease in people living with HIV and prediabetes","volume":"13","author":"Kamolvisit","year":"2021","journal-title":"Cureus"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"56","author":"Tokushige","year":"2021","journal-title":"J Gastroenterol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.0284","article-title":"Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis","volume":"16","author":"Said","year":"2017","journal-title":"Ann Hepatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004947","article-title":"Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials","volume":"95","author":"He","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"CD005166","DOI":"10.1002\/14651858.CD005166.pub2","article-title":"Drugs improving insulin resistance for non-alcoholic fatty liver disease and\/or non-alcoholic steatohepatitis","volume":"24","author":"Angelico","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.03.016","article-title":"The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis","volume":"55","author":"Mahady","year":"2011","journal-title":"J Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00243.2015","article-title":"Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine n-methyltransferase-deficient mice","volume":"310","author":"van der Veen","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2165\/11538100-000000000-00000","article-title":"Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents","volume":"70","author":"Derosa","year":"2010","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-0015","article-title":"Diet\/Exercise versus pioglitazone: effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers","volume":"91","author":"Shadid","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1354","article-title":"Pioglitazone and bladder cancer risk: a systematic review and meta-analysis","volume":"7","author":"Tang","year":"2018","journal-title":"Cancer Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabetes Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"i3903","DOI":"10.1136\/bmj.i3903","article-title":"Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries","volume":"354","author":"Korhonen","year":"2016","journal-title":"BMJ"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2017.11.002","article-title":"An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis","volume":"135","author":"Davidson","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"B58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1471-2261-14-129","article-title":"The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies","volume":"14","author":"Varas-Lorenzo","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735824","article-title":"Effects of anti-diabetic drugs on fracture risk: A systematic review and network meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar","year":"2003","journal-title":"Endocr Pract"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1111430\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T09:09:15Z","timestamp":1680080955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1111430\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":61,"alternative-id":["10.3389\/fendo.2023.1111430"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1111430","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"article-number":"1111430"}}